CN103222995B - 白子菜在制备护肝药物或保健食品中的应用 - Google Patents
白子菜在制备护肝药物或保健食品中的应用 Download PDFInfo
- Publication number
- CN103222995B CN103222995B CN201310179552.9A CN201310179552A CN103222995B CN 103222995 B CN103222995 B CN 103222995B CN 201310179552 A CN201310179552 A CN 201310179552A CN 103222995 B CN103222995 B CN 103222995B
- Authority
- CN
- China
- Prior art keywords
- gynura divaricata
- extract
- water
- application
- liver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241001558017 Gynura Species 0.000 title claims abstract description 41
- 235000013305 food Nutrition 0.000 title abstract description 3
- 239000002445 liver protective agent Substances 0.000 title abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 34
- 239000000284 extract Substances 0.000 claims description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- 239000003814 drug Substances 0.000 claims description 19
- 235000013402 health food Nutrition 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 9
- 239000000469 ethanolic extract Substances 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 7
- -1 reflux Substances 0.000 claims description 7
- 238000010992 reflux Methods 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 238000003809 water extraction Methods 0.000 abstract description 14
- 238000000605 extraction Methods 0.000 abstract description 13
- 241000699670 Mus sp. Species 0.000 abstract description 9
- 210000002966 serum Anatomy 0.000 abstract description 9
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 abstract description 8
- 230000017074 necrotic cell death Effects 0.000 abstract description 7
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 abstract description 3
- 108010082126 Alanine transaminase Proteins 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 3
- 206010067125 Liver injury Diseases 0.000 abstract description 2
- 210000005229 liver cell Anatomy 0.000 abstract description 2
- 230000005764 inhibitory process Effects 0.000 abstract 2
- 108090000340 Transaminases Proteins 0.000 abstract 1
- 231100000439 acute liver injury Toxicity 0.000 abstract 1
- 230000036425 denaturation Effects 0.000 abstract 1
- 238000004925 denaturation Methods 0.000 abstract 1
- 238000011160 research Methods 0.000 abstract 1
- 102000014898 transaminase activity proteins Human genes 0.000 abstract 1
- 239000000843 powder Substances 0.000 description 12
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 10
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 9
- 229960004756 ethanol Drugs 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 206010028851 Necrosis Diseases 0.000 description 6
- 235000019219 chocolate Nutrition 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 5
- 239000004375 Dextrin Substances 0.000 description 4
- 229920001353 Dextrin Polymers 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 235000019425 dextrin Nutrition 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- 210000003494 hepatocyte Anatomy 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 210000004969 inflammatory cell Anatomy 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- JMZOMFYRADAWOG-UHFFFAOYSA-N methyl 7-methoxy-4-(7-methoxy-5-methoxycarbonyl-1,3-benzodioxol-4-yl)-1,3-benzodioxole-5-carboxylate Chemical compound COC(=O)C1=CC(OC)=C2OCOC2=C1C1=C2OCOC2=C(OC)C=C1C(=O)OC JMZOMFYRADAWOG-UHFFFAOYSA-N 0.000 description 4
- CNNRPFQICPFDPO-UHFFFAOYSA-N octacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCO CNNRPFQICPFDPO-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- TYWMIZZBOVGFOV-UHFFFAOYSA-N tetracosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCO TYWMIZZBOVGFOV-UHFFFAOYSA-N 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 231100000753 hepatic injury Toxicity 0.000 description 3
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 3
- CBFCDTFDPHXCNY-UHFFFAOYSA-N icosane Chemical compound CCCCCCCCCCCCCCCCCCCC CBFCDTFDPHXCNY-UHFFFAOYSA-N 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 2
- 229960002666 1-octacosanol Drugs 0.000 description 2
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 241000904014 Pappus Species 0.000 description 2
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 2
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 2
- QXMNTPFFZFYQAI-IMDKZJJXSA-N beta-sitosterol 3-O-beta-D-glucopyranoside Natural products CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]5C[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C(C)C QXMNTPFFZFYQAI-IMDKZJJXSA-N 0.000 description 2
- 235000019636 bitter flavor Nutrition 0.000 description 2
- NPJICTMALKLTFW-OFUAXYCQSA-N daucosterol Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CC[C@@H](CC)C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NPJICTMALKLTFW-OFUAXYCQSA-N 0.000 description 2
- QDFKFNAHVGPRBL-UHFFFAOYSA-N daucosterol Natural products CCC(CCC(C)C1CCC2C1CCC3C2(C)CC=C4CC(CCC34C)OC5OC(CO)C(O)C(O)C5O)C(C)C QDFKFNAHVGPRBL-UHFFFAOYSA-N 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- UTOPWMOLSKOLTQ-UHFFFAOYSA-N octacosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCC(O)=O UTOPWMOLSKOLTQ-UHFFFAOYSA-N 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 2
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 2
- 229940032091 stigmasterol Drugs 0.000 description 2
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 2
- 235000016831 stigmasterol Nutrition 0.000 description 2
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 241001573881 Corolla Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- KVSNMTUIMXZPLU-UHFFFAOYSA-N D:A-friedo-oleanane Natural products CC12CCC3(C)C4CC(C)(C)CCC4(C)CCC3(C)C2CCC2(C)C1CCCC2C KVSNMTUIMXZPLU-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- JUUHNUPNMCGYDT-UHFFFAOYSA-N Friedelin Natural products CC1CC2C(C)(CCC3(C)C4CC(C)(C)CCC4(C)CCC23C)C5CCC(=O)C(C)C15 JUUHNUPNMCGYDT-UHFFFAOYSA-N 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 244000045531 Gynura pseudochina Species 0.000 description 1
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 1
- 241000735488 Hypoestes Species 0.000 description 1
- 241001582888 Lobus Species 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 206010068676 Pneumoretroperitoneum Diseases 0.000 description 1
- 208000005727 Retropneumoperitoneum Diseases 0.000 description 1
- VWDLOXMZIGUBKM-AMHNIKBJSA-N Stigmasterol-3-O-beta-D-glucopyranoside Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@@H]4[C@@](C)([C@@H]([C@@H](/C=C/[C@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 VWDLOXMZIGUBKM-AMHNIKBJSA-N 0.000 description 1
- 240000004460 Tanacetum coccineum Species 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 206010051373 Wound haemorrhage Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- CGZZMOTZOONQIA-UHFFFAOYSA-N cycloheptanone Chemical compound O=C1CCCCCC1 CGZZMOTZOONQIA-UHFFFAOYSA-N 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- OFMXGFHWLZPCFL-SVRPQWSVSA-N friedelin Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3CCC(=O)[C@@H]1C OFMXGFHWLZPCFL-SVRPQWSVSA-N 0.000 description 1
- MFVJCHSUSSRHRH-UHFFFAOYSA-N friedeline Natural products CC1(C)CCC2(C)CCC3C4(C)CCC5C(C)(C)C(=O)CCC5(C)C4CCC3(C)C2C1 MFVJCHSUSSRHRH-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 206010019692 hepatic necrosis Diseases 0.000 description 1
- 230000007866 hepatic necrosis Effects 0.000 description 1
- 210000002989 hepatic vein Anatomy 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- VAMFXQBUQXONLZ-UHFFFAOYSA-N n-alpha-eicosene Natural products CCCCCCCCCCCCCCCCCCC=C VAMFXQBUQXONLZ-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000001007 puffing effect Effects 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- VWDLOXMZIGUBKM-AUGXRQBFSA-N stigmasterol 3-O-beta-D-glucoside Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VWDLOXMZIGUBKM-AUGXRQBFSA-N 0.000 description 1
- VWDLOXMZIGUBKM-OFUAXYCQSA-N stigmasterol-3-yl-O-beta-D-glucopyranoside Natural products CC[C@H](C=C[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C(C)C VWDLOXMZIGUBKM-OFUAXYCQSA-N 0.000 description 1
- VWDLOXMZIGUBKM-UHFFFAOYSA-N stigmasterol-3beta-O-D-glucoside Natural products C1CC2(C)C3CCC4(C)C(C(C)C=CC(CC)C(C)C)CCC4C3CC=C2CC1OC1OC(CO)C(O)C(O)C1O VWDLOXMZIGUBKM-UHFFFAOYSA-N 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Botany (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medical Informatics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明公开了白子菜在制备护肝药物或保健食品中的应用。本发明经研究发现对于CCl4所致的小鼠急性肝损伤，白子菜醇提、水提高剂量组有明显地抑制作用，表现为降低血清谷丙、谷草转氨酶，减轻肝细胞变性、坏死。
Description
技术领域
本发明涉及中药领域，尤其涉及中药单方白子菜在制药及保健食品中的用途。
背景技术
白子菜，又名白背三七，为菊科植物白子菜Gynura divaricata(L.)DC.[G.oualis DC.；G.pseudo-china(L.)DC.]的全草。白子菜别名大肥牛(《广州植物志》)、土生地、白仔菜药、散血姜(《广西药植图志》)，土田七(《广西中药志》)，枪刀药、清心菜、白血皮菜、胡豆七、大晕病药、台湾仙草、益寿神草、生命树、龙仙草、神草等。白子菜为多年生草本，高30-60厘米，茎直立，或基部多少斜升，木质，干时具条棱，不分枝或有时上部有花序枝，无毛或被短柔毛，稍带紫色。叶质厚，通常集中于下部，具柄或近无柄；叶片卵形，椭圆形或倒披针形，长2-15厘米，宽1.5-5厘米，顶端钝或急尖，基部楔状狭或下延成叶柄，近截形或微心形，边缘具粗齿，有时提琴状裂，稀全缘，上面绿色，下面带紫色，侧脉3-5对，细脉常连结成近平行的长圆形细网，干时呈清晰的黑线，两面被短柔毛；叶柄长0.5-4厘米，有短柔毛，基部有卵形或半月形具齿的耳。上部叶渐小，苞叶状，狭披针形或线形，羽状浅裂，无柄，略抱茎。头状花序直径1.5-2厘米，通常(2)3-5个在茎或枝端排成疏伞房状圆锥花序，常呈叉状分枝；花序梗长1-15厘米，被密短柔毛，具1-3线形苞片。总苞钟状，长8-10毫米，宽6-8毫米，基部有数个线状或丝状小苞片；总苞片1层，11-14个，狭披针形，长8-10毫米，宽1-2毫米，顶端渐尖，呈长三角形，边缘干膜质，背面具3脉，被疏短毛或近无毛。小花橙黄色，有香气，略伸出总苞；花冠长11-15毫米，管部细，长9-11毫米，上部扩大，裂片长圆状卵形，顶端红色，尖。花药基部钝或徽箭形；花柱分枝细，有锥形附器，被乳头状毛。瘦果圆柱形，长约5毫米，褐色，具10条肋，被微毛；冠毛白色，绢毛状，长10-12毫米。花果期8-10月。药材及饮片的性状为根茎块状，具细长须根。茎圆柱形，棕紫色，被短毛，叶互生，多皱缩，完整叶片呈长卵形至长圆状倒卵形，长5-15cm，宽2.5-8cm，先端钝或短尖，基部有时有两耳，叶缘具不规则缺刻及锯齿，上下表面均具柔毛。有时可见头状花序或总苞。瘦果深褐色，冠毛白色。气微，味淡。白子菜分布于广东（广州、南海）、海南（澄迈、崖县、万宁、保亭、琼中、琼山等）、香港、云南（景东、红河、绿春）。越南北部也有分布。功效清热凉血；活血止痛；止血。用于咳嗽；支气管炎、肺结核；疮疡；痈肿；烫伤；跌打损伤；风湿痛；崩漏；外伤出血。治百日咳，骨折，创伤出血，痈肿疮疖。白子菜含有正二十烷（n-Eicosane），二十四烷醇（Tetracosanol），二十八烷酸（Octacosanoicacid），二十八烷醇（Octacosyl alcohol），棕榈酸（Palmitic acid），豆甾醇-3-O-β-D-吡喃葡萄糖苷（Stigmasterol-3-O-β-D-glucopyranoside），豆甾醇（Stigmasterol），β-谷甾醇（β-Sitosterol），胡萝卜苷（Daucosterol），木栓酮（Friedelin）等成分。现代研究表明其具有一定的降血糖作用。
发明内容
本发明的目的是提供白子菜的一种新的用途，其能有效保护肝脏。
本发明的目的是这样实现的：白子菜在制备护肝药物或保健食品中的应用。
所述的护肝药物或保健食品为治疗肝炎的药物或保健食品。
所述药物是以白子菜提取物与常规用量的医学上可接受的辅料混合制成的临床上可接受的制剂。
所述的白子菜提取物为水提物或醇提物。
所述水提物的制备方法的步骤包括：白子菜加8～12倍水，煎煮1.5～2小时，残渣再加5～8倍量水煎煮1～1.5小时，合并提取液后过滤，浓缩。
所述醇提物的制备方法的步骤包括：白子菜加8～12倍75％～90％乙醇，回流提取1.5～2小时，残渣再加75％～90％倍量水煎煮1～1.5小时，合并提取液后过滤，回收乙醇，浓缩。
所述的制剂是临床上可接受的颗粒剂、胶囊剂、片剂或口服液。
本发明经研究发现对于CCl4所致的小鼠急性肝损伤，白子菜醇提、水提高剂量组有明显地抑制作用，表现为降低血清谷丙、谷草转氨酶，减轻肝细胞变性、坏死。
具体实施方式
以下是本发明的一些具体实施例，用于进一步说明本发明，但本发明并不仅限于这些实施例。
实施例1（水提）
白子菜加8倍水提取，第1次提取2小时，第二次加8倍量水提取1.5小时，提取液合并后过滤，浓缩，干燥得棕褐色粉末状即可，浸膏得率（最后的粉末得率除以投料的药材重量）为6～10％。
实施例2（水提）
白子菜加10倍水提取，第1次提取1.5小时，第二次加6倍量水提取1.2小时，提取液合并后过滤，浓缩，干燥得棕褐色粉末状即可，浸膏得率为6～10％。
实施例3（水提）
白子菜加12倍水提取，第1次提取1.5小时，第二次加5倍量水提取1小时，提取液合并后过滤，浓缩，干燥得棕褐色粉末状即可，浸膏得率为6～10％。
实施例4（醇提）
白子菜加10倍80％酒精，回流提取2小时，残渣再加80％倍量水煎煮1.5小时，合并提取液后过滤，回收乙醇，浓缩，干燥得棕褐色粉末状即可，浸膏得率为6～8％。
实施例5（醇提）
白子菜加8倍90％酒精，回流提取1.5小时，残渣再加90％倍量水煎煮1小时，合并提取液后过滤，回收乙醇，浓缩，干燥得棕褐色粉末状即可，浸膏得率为6～8％。
实施例6（醇提）
白子菜加12倍75％酒精，回流提取2小时，残渣再加75％倍量水煎煮1.5小时，合并提取液后过滤，回收乙醇，浓缩，干燥得棕褐色粉末状即可，浸膏得率为6～8％。
实施例7（颗粒剂）
处方：按重量份计算，实施例1所得水提取物1份、蔗糖2.5份、糊精1.5份。
制法：将提取物粉加入蔗糖与糊精，混匀，制成颗粒，干燥，分装,即得。
性状：本品为黄褐色的颗粒；味微甜、苦。
用法与用量：开水冲服，一次7.5g，一日2～3次。
实施例8（颗粒剂）
处方：按重量份计算，实施例3所得水提取物1份、蔗糖2.5份、糊精1.5份。
制法：将提取物粉加入蔗糖与糊精，混匀，制成颗粒，干燥，分装,即得。
性状：本品为黄褐色的颗粒；味微甜、苦。
用法与用量：开水冲服，一次2.5g，一日2～3次。
实施例9（胶囊剂）
处方：按重量份计算，实施例4所得醇提取物1份、淀粉2份。
制法：将提取物粉末加入淀粉，混匀，制成颗粒，干燥，装入胶囊即得。
性状：本品为胶囊剂，内容物为深棕色的颗粒或粉末；味微苦。
用法与用量：口服，一次3粒，一日2～3次。
实施例10（片剂）
处方：按重量份计算，实施例5所得醇提取物1份、淀粉2份、硬脂酸镁适量。
制法：将提取物粉末加入淀粉，混匀，制成颗粒，干燥，加入硬脂酸镁，压片即得。
性状：本品为深棕色片剂，味微苦。
用法与用量：口服，一次3粒，一日2～3次。
以下通过实验来进一步说明本发明的药物作用原理和有益效果：
一、实验材料及方法
1、受试药物：白子菜水提物（1.3g生药/ml）和醇提物（2.6g生药/ml）；
联苯双酯滴丸，广州星群（药业）股份有限公司，批号：JF40021。
2、动物NIH小鼠，SPF级，雄性，体重18～22克。实验动物质量合格证号：2006A051；SPF级实验动物环境条件合格证号：2006B023；SPF级实验动物生产许可证号：SCXK粤2011-0015；动物由南方医科大学动物实验中心提供。
3、主要的化学试剂及检测仪器：丙氨酸氨基转移酶（ALT）测定试剂盒，中生北控生物科技股份有限公司，批号：121881；天门冬氨酸氨基转移酶（AST）测定试剂盒，中生北控生物科技股分有限公司，批号：120921；四氯化碳溶液，分析纯，天津市富宁精细化工有限公司，批号：111010；甲醛溶液，分析纯，批号20111007，广东光华科技股份有限公司；无水乙醇，分析纯，批号20110416，天津市进丰化工有限公司；二甲苯，分析纯，批号20101224，广东光华化学厂有限公司；苏木色精，生物染色素，批号060408，北京鼎国生物技术有限责任公司Fluka进口分装；曙红Y，生物染色素，批号20050912，中国华东师范大学化工厂；ECHO LCD生化仪由意大利爱康公司生产。OLYMPUS AU5421型全自动生化分析仪，日本OLYMPUS公司生产；OLYMPUS BH－2荧光显微镜，日本OLYMPUS公司生产；BECKMANTM30型低温离心机，美国BACKMAN公司生产；LEICA RM2135型切片机，德国LEICA公司生产；SARTORIUS电子天平，德国SARTORIUS公司生产。
4、实验方法及剂量：动物分为正常对照组、模型组、联苯双酯组（0.2g/kg）、水提高剂量组（1.12g/kg）、水提中剂量组（0.56g/kg）、水提低剂量组（0.28g/kg）、醇提高剂量组（1.12g/kg）、醇提中剂量组（0.56g/kg）、醇提低剂量组（0.28g/kg）。每组12只动物。连续灌胃给药7天，每天1次。正常对照组及模型组灌胃同体积的自来水。灌胃容积为0.25ml/10克小鼠，自由摄食。末次灌胃1个小时后腹腔注射0.12%（体积比）四氯化碳（用纯花生油配制）0.2ml/只。禁食不禁水，16小时后摘眼球取血，离心取血清，检测谷丙转氨酶及谷草转氨酶。
5、病理学检查取肝脏左叶用中性福尔马林固定，常规脱水，石蜡包埋切片（4微米），HE染色，光镜下观察肝组织病理学变化。将肝组织损伤程度分为4级（1）：0级(－)，肝组织结构正常，无明显变性、坏死及炎症细胞浸润；Ⅰ级(+)，肝小叶结构尚正常，可见部分肝细胞混浊肿胀，气球样变或脂肪变性，散在点状坏死；Ⅱ级（++），肝小叶结构不清，可见明显的灶状坏死，伴有炎症细胞浸润；Ⅲ级（+++），肝小叶结构不清、可见明显的片状坏死，伴有炎症细胞浸润。
6、实验数据用及等级/频数表资料表示，采用spss8.0统计软件One-Way ANOVALSD或DunnettT3法及Nonparametric Test2Independent Samples Tests法进行数据处理。
二、检测结果：
1．肝功能检测结果
小鼠血清谷丙转氨酶、谷草转氨酶检测结果见表1。
表1：各实验组小鼠血清谷丙、谷草转氨酶检测结果
注：*与模型组比较，P<0.05；**与模型组比较，P<0.01。
由表1可见，模型组与正常组比较，血清谷丙、谷草转氨酶均明显升高（P<0.01）；联苯双酯组血清谷丙转氨酶明显降低（P<0.01）；白子菜水提物及醇提物高剂量组血清谷丙、谷草转氨酶均明显降低（P<0.05）；白子菜醇提物中剂量组谷草转氨酶明显降低（P<0.05）。
2、对急性肝损伤小鼠肝组织病理学损伤的影响
病理切片结果表明，正常对照组小鼠肝组织结构正常，肝细胞以中央静脉为中心呈放射状排列，肝细胞索、肝血窦排列规则，肝小叶结构完整，可见部分动物肝细胞轻度肿胀、点坏死等病理变化。CCl4模型组小鼠可见大多数肝细胞以环中央静脉分布出现浑浊肿胀，细胞质疏松化，有的呈气球样变。以肝小叶中央静脉和肝被膜下分布的肝细胞点状、灶性或片状坏死，伴炎性细胞浸润等病理改变。联苯双酯组及白子菜醇提、水提高剂量组能明显减轻肝细胞坏死（P<0.05），表明白子菜醇提、水提高剂量组对CCl4腹腔注射所致肝损伤有保护作用，病理检查结果见表2。
表2：各实验组小鼠对CCl4所致急性肝损伤组织病理学的影响
注：P值为各组与模型比较的结果。
三、实验总结：
通过本实验表明，对于CCl4所致小鼠急性肝损伤，白子菜醇提、水提高剂量组有明显地抑制作用，表现为降低血清谷丙、谷草转氨酶，减轻肝细胞变性、坏死。
Claims (5)
1.白子菜在制备治疗肝炎的药物或保健食品中的应用，所述药物或保健食品是由白子菜提取物与常规用量的医学上可接受的辅料混合制成的临床上可接受的制剂。
2.根据权利要求1所述的白子菜在制备护肝药物或保健食品中的应用，其特征在于：所述的白子菜提取物为水提物或醇提物。
3.根据权利要求2所述的白子菜在制备护肝药物或保健食品中的应用，其特征在于：所述水提物的制备方法的步骤包括：白子菜加8～12倍水，煎煮1.5～2小时，残渣再加5～8倍量水煎煮1～1.5小时，合并提取液后过滤，浓缩。
4.根据权利要求2所述的白子菜在制备护肝药物或保健食品中的应用，其特征在于：所述醇提物的制备方法的步骤包括：白子菜加8～12倍75％～90％乙醇，回流提取1.5～2小时，残渣再加75％～90％倍量水煎煮1～1.5小时，合并提取液后过滤，回收乙醇，浓缩。
5.根据权利要求1所述的白子菜在制备护肝药物或保健食品中的应用，其特征在于：所述的制剂是临床上可接受的颗粒剂、胶囊剂、片剂或口服液。
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310179552.9A CN103222995B (zh) | 2013-05-15 | 2013-05-15 | 白子菜在制备护肝药物或保健食品中的应用 |
| SG11201501648SA SG11201501648SA (en) | 2013-05-15 | 2014-04-28 | Application of gynura divaricata in preparing medicine or health food for treating hepatitis |
| KR1020157003623A KR20150036538A (ko) | 2013-05-15 | 2014-04-28 | 백자채(gynura divaricata)의 간염 치료 약물 또는 건강식품 제조에의 응용 |
| JP2015524634A JP2015524813A (ja) | 2013-05-15 | 2014-04-28 | タカサゴサンシチソウの肝炎を治療する薬物又は保健用食品の製造への応用 |
| PCT/CN2014/076376 WO2014183551A1 (zh) | 2013-05-15 | 2014-04-28 | 白子菜在制备治疗肝炎的药物或保健食品中的应用 |
| GB1507323.2A GB2522146B (en) | 2013-05-15 | 2014-04-28 | Use of Gynura divaricata in Preparing Medicaments or Food for Treating Hepatitis |
| HK16100444.4A HK1212589A1 (zh) | 2013-05-15 | 2016-01-15 | 白子菜在製備治療肝炎的藥物或食品中的應用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310179552.9A CN103222995B (zh) | 2013-05-15 | 2013-05-15 | 白子菜在制备护肝药物或保健食品中的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103222995A CN103222995A (zh) | 2013-07-31 |
| CN103222995B true CN103222995B (zh) | 2014-09-03 |
Family
ID=48833791
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310179552.9A Active CN103222995B (zh) | 2013-05-15 | 2013-05-15 | 白子菜在制备护肝药物或保健食品中的应用 |
Country Status (7)
| Country | Link |
|---|---|
| JP (1) | JP2015524813A (zh) |
| KR (1) | KR20150036538A (zh) |
| CN (1) | CN103222995B (zh) |
| GB (1) | GB2522146B (zh) |
| HK (1) | HK1212589A1 (zh) |
| SG (1) | SG11201501648SA (zh) |
| WO (1) | WO2014183551A1 (zh) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103230444B (zh) * | 2013-05-15 | 2014-03-19 | 李伟权 | 一种降脂护肝中药组合物及其制备方法和应用 |
| CN103222995B (zh) * | 2013-05-15 | 2014-09-03 | 李伟权 | 白子菜在制备护肝药物或保健食品中的应用 |
| CN110368411B (zh) * | 2019-08-02 | 2021-08-06 | 龙岩学院 | 一种白背天葵多酚的提取工艺及其分离纯化方法 |
| CN112655601A (zh) * | 2020-12-02 | 2021-04-16 | 中国水产科学研究院淡水渔业研究中心 | 一种四氯化碳诱导淡水鱼急性肝肠联合损伤模型的建立及其应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102631391A (zh) * | 2012-05-15 | 2012-08-15 | 李伟权 | 白子菜在制备降脂药物或保健食品中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10251154A (ja) * | 1997-03-13 | 1998-09-22 | Suntory Ltd | 肝炎抑制組成物 |
| EP1718167A4 (en) * | 2004-01-31 | 2010-07-14 | Kiyoung Kim | COMPOSITION COMPRISING HOVENIA DULCIS PLANT EXTRACT, LINDERA OBTUSILOBA BLUME EXTRACT, OR HERB MIXTURE EXTRACT THEREOF |
| JP2008074807A (ja) * | 2006-09-25 | 2008-04-03 | Oriza Yuka Kk | 肝保護剤 |
| CN101485706A (zh) * | 2008-01-19 | 2009-07-22 | 郑乐建 | 抗氧化自由基祛面斑作用的白背三七及其软胶囊制剂 |
| JP5422200B2 (ja) * | 2008-12-26 | 2014-02-19 | 株式会社ヤクルト本社 | 肝機能障害改善剤 |
| CN103222995B (zh) * | 2013-05-15 | 2014-09-03 | 李伟权 | 白子菜在制备护肝药物或保健食品中的应用 |
-
2013
- 2013-05-15 CN CN201310179552.9A patent/CN103222995B/zh active Active
-
2014
- 2014-04-28 JP JP2015524634A patent/JP2015524813A/ja active Pending
- 2014-04-28 SG SG11201501648SA patent/SG11201501648SA/en unknown
- 2014-04-28 WO PCT/CN2014/076376 patent/WO2014183551A1/zh active Application Filing
- 2014-04-28 KR KR1020157003623A patent/KR20150036538A/ko not_active Application Discontinuation
- 2014-04-28 GB GB1507323.2A patent/GB2522146B/en active Active
-
2016
- 2016-01-15 HK HK16100444.4A patent/HK1212589A1/zh unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102631391A (zh) * | 2012-05-15 | 2012-08-15 | 李伟权 | 白子菜在制备降脂药物或保健食品中的应用 |
Non-Patent Citations (2)
| Title |
|---|
| 用于治疗乙肝后肝硬化腹水的民族药调查研究;马原野等;《中国民族民间医药》;20110831;第1-2页 * |
| 马原野等.用于治疗乙肝后肝硬化腹水的民族药调查研究.《中国民族民间医药》.2011, |
Also Published As
| Publication number | Publication date |
|---|---|
| GB201507323D0 (en) | 2015-06-10 |
| GB2522146A (en) | 2015-07-15 |
| CN103222995A (zh) | 2013-07-31 |
| JP2015524813A (ja) | 2015-08-27 |
| SG11201501648SA (en) | 2016-01-28 |
| HK1212589A1 (zh) | 2016-06-17 |
| WO2014183551A1 (zh) | 2014-11-20 |
| KR20150036538A (ko) | 2015-04-07 |
| GB2522146B (en) | 2016-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tang et al. | Review on research of the phytochemistry and pharmacological activities of Celosia argentea | |
| CN103222995B (zh) | 白子菜在制备护肝药物或保健食品中的应用 | |
| CN101411761A (zh) | 苹果属花楸苹果组植物的新用途 | |
| CN102526499A (zh) | 一种药物组合物及其制备方法和用途 | |
| CN102631391A (zh) | 白子菜在制备降脂药物或保健食品中的应用 | |
| CN102114170B (zh) | 防治心肌缺血再灌注损伤的中药组合物及其制备方法 | |
| CN105410569A (zh) | 一种对酒精性肝损伤具有保护作用的桑椹饮料的制备方法 | |
| Rahman et al. | Acmella radicans (Jacq.) RK Jansen (Asteraceae)-a new angiosperm record for Bangladesh | |
| CN104257811A (zh) | 一种保肝的食品、保健品或药物组合物 | |
| CN104161850B (zh) | 一种中药提取物的制备方法及其制备的中药提取物和用途 | |
| CN103860706B (zh) | 一种具有保护酒精性肝损伤功能的纯中药养生制剂 | |
| CN1546117A (zh) | 治疗产后缺乳的口服液及其生产方法 | |
| CN103977390A (zh) | 一种生姜洋葱药酒组合物的制备方法及其用途 | |
| Umakrithika | A comprehensive overview of plant genus: Lindernia | |
| CN1939383B (zh) | 红背叶根在制备治疗慢性肝炎药物中的应用 | |
| CN106928376A (zh) | 山茱萸多糖的分离方法及其应用 | |
| CN102920991B (zh) | 山药多糖和山药蛋白质的组合物的用途 | |
| CN101269175A (zh) | 痔舒适洗液的质量控制方法 | |
| CN109527568A (zh) | 一种改善血瘀体质的功能食品及其制备方法 | |
| CN108721520A (zh) | 一种用于提高免疫力的口服液及其制备方法 | |
| CN110151938B (zh) | 一种藤茶制剂的新用途 | |
| CN102258555B (zh) | 芫根总皂苷制备降血糖药物的用途 | |
| CN104544065A (zh) | 一种含鱼腥草的能辅助降血糖的保健食品 | |
| CN101129604A (zh) | 一种降糖中药及其制备方法 | |
| Charles et al. | Hormonal and Histological Effects of Star Fruit, Averrhoea carambola Fruit Extract on Female Reproduction of Wistar Rat, Rattus Norvegicus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |